1. Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
- Author
-
Kazuto Kozaka, Akira Mitoro, Masahiko Hirota, Mamoru Takenaka, Katsuya Kitamura, Kenji Kimura, Chie Kayaba, Hiroki Haradome, Shuji Isaji, Keisho Kataoka, Yousuke Nakai, Ryoji Nakamura, Kazunori Takeda, Toshifumi Gabata, Toshihiko Mayumi, Shin Miura, Atsushi Masamune, Tetsuhide Ito, Eisuke Iwasaki, Koki Yamagiwa, Tetsuya Ito, Etsuji Ishida, Hiroyuki Maguchi, Tooru Shimosegawa, Tsuyoshi Sanuki, Koji Ikeda, Yoshifumi Takeyama, Morihisa Hirota, and Hirotaka Sawano
- Subjects
Adult ,Male ,medicine.medical_specialty ,Analgesic ,Context (language use) ,Pancreatic necrosis ,Guanidines ,Severity of Illness Index ,Gastroenterology ,Fentanyl ,law.invention ,Young Adult ,Japan ,Randomized controlled trial ,law ,Internal medicine ,Clinical endpoint ,Humans ,Infusions, Intra-Arterial ,Medicine ,Protease Inhibitors ,Adverse effect ,Continuous regional arterial infusion ,Aged ,Original Article—Liver, Pancreas, and Biliary Tract ,Pancreatitis, Acute Necrotizing ,business.industry ,Middle Aged ,medicine.disease ,Acute pancreatitis ,Benzamidines ,Treatment Outcome ,medicine.anatomical_structure ,Protease inhibitor ,Pancreatitis ,Administration, Intravenous ,Female ,Tomography, X-Ray Computed ,business ,Pancreas ,medicine.drug - Abstract
BackgroundContinuous regional arterial infusion (CRAI) of protease inhibitor nafamostat mesilate (NM) is used in the context of predicted severe acute pancreatitis (SAP) to prevent the development of pancreatic necrosis. Although this therapy is well known in Japan, its efficacy and safety remain unclear.MethodsThis investigator-initiated and -driven, multicenter, open-label, randomized, controlled trial (UMIN000020868) enrolled 39 patients with predicted SAP and low enhancement of the pancreatic parenchyma on computed tomography (CT). Twenty patients were assigned to the CRAI group, while 19 served as controls and were administered NM at the same dose intravenously (IV group). The primary endpoint was the development of pancreatic necrosis as determined by CT on Day 14, judged by blinded central review.ResultsThere was no difference between the CRAI and IV groups regarding the percentages of participants who developed pancreatic necrosis (more than 1/3 of the pancreas: 25.0%, range 8.7–49.1% vs. 15.8%, range 3.4–39.6%, respectively,P = 0.694; more than 2/3 of the pancreas: 20%, range 5.7–43.7% vs. 5.3%, range 0.1–26.0%, respectively,P = 0.341). The early analgesic effect was evaluated based on 24-h cumulative fentanyl consumption and additional administration by intravenous patient-controlled analgesia. The results showed that the CRAI group used significantly less analgesic. There were two adverse events related to CRAI, namely bleeding and splenic infarction.ConclusionsCRAI with NM did not inhibit the development of pancreatic necrosis although early analgesic effect of CRAI was superior to that of IV. Less-invasive IV therapy can be considered a viable alternative to CRAI therapy.
- Published
- 2019
- Full Text
- View/download PDF